Home > Inhibitors & Agonists > Others
Cat. No. Product name CAS No.
DCC5506 way-133537

ATP-sensitive potassium channel opener

177476-74-3
DCC5507 Way-151693

Inhibitor of human collagenase-3 (MMP-13)

206551-25-9
DCC5508 Way-170523

Potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3)

307002-73-9
DCC5509 Way-171230

Inhibitor of matrix metalloproteinase-1 (MMP-1)

DCC5510 Way-260022

Potent and Selective Inhibitor of the Norepinephrine Transporter

850692-43-2
DCC5511 Way-316606 Hydrochloride

Secreted frizzled-related protein-1 (sFRP-1) modulaitor

1781835-02-6
DCC5512 Wb-308

Novel inhibitor of The epidermal growth factor receptor (EGFR), decreasing NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis.

1373764-87-4
DCC5513 Wb4-24

Non-peptide GLP-1 receptor agonist, blocking inflammatory nociception by stimulating β-endorphin release from spinal microglia

DCC5514 Wck5153

Novel Inhibitor of PBP2, Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones

1436862-38-2
DCC5515 We-14 Tfa Salt

Highly conserved neuropeptide derived from Chromogranin A (Parathyroid Secretory Protein 1)

115136-18-0
DCC5516 Web2347

Novel very potent and long acting hetrazepinoic PAF-antagonist

114800-19-0
DCC5517 Wen05-03

Novel inhibitor of type III secretion system ATPase EscN from enteropathogenic Eecherichia coli

DCC5518 Wfq-228

Novel fluoroquinolone antibiotic with potent antimicrobial activity, showing the potential to overcome major drug resistance; its antimicrobial activity was less affected by both pump-mediated efflux and QRDR mutations in P. aeruginosa compared with LVX a

DCC5519 Whz-04

Novel Anti-malarial Plasmodium-Selective Proteasome Inhibitor

DCC5520 Win-35428

Dopamine reuptake inhibitor, also having some SERT affinity

50370-56-4
DCC5521 Win-64338

B2 bradykinin receptor antagonist

151039-63-3
DCC5522 Withangulatin A

Natural potent antitumoragent, targeting sarco/endoplasmic reticulum calcium-ATPase (SERCA)2

120824-03-5
DCC5523 Wj35435

Novel dual inhibitor of histone deacetylase and topoisomerase I

1620054-84-3
DCC5524 Wjd008

Novel potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR), preventing PI3K signaling and inhibiting the proliferation of transformed cells with oncogenic PI3K mutant

1309087-83-9
DCC5525 Wms-1410

Novel GluN2B-specific NMDAR antagonist, completely preventing the decrease in insulin secretion of about 32 % provoked by a 24-h-treatment with NMDA/glycine, eliminating NMDA-induced changes in the oxidation status of the islet cells and elevating the sen

DCC5526 Wms-2539

Potent uncompetitive NMDA receptor antagonist

DCC5527 Wn1316

Unique neuroprotectant against oxidative injury, being a highly promising remedy for the treatment of amyotrophic lateral sclerosis (ALS)

1356959-71-1
Page 1122 / Total 1149 FirstPrevNextLastGoto